RE
MREO

RBC Europe’s Mereo BioPharma MREO Stock Holding History

RBC Europe’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-184
Closed -$659 – 1221
2020
Q4 		$659 Buy
+184
New +$461 ﹤0.01% 1104

Other funds holding MREO

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

RBC Europe's MREO Position: Q1 2021 in Review

RBC Europe sold out of Mereo BioPharma (MREO) in Q1 2021, closing a stake of 184 shares — an estimated $659 sold.

RBC Europe first reported a position in MREO in Q4 2020 and held it in 1 quarter. The position peaked at $659 in Q4 2020. 66 funds tracked by Wall St. Rank hold MREO as of Q1 2021.

  • RBC Europe reported no remaining Mereo BioPharma position as of Q1 2021 after selling out during the quarter.
  • RBC Europe sold 184 Mereo BioPharma shares in Q1 2021, an estimated $659.
  • RBC Europe first reported a position in Mereo BioPharma in Q4 2020 and held it in 1 quarter.
  • RBC Europe's Mereo BioPharma position peaked at $659 in Q4 2020.
  • 66 funds tracked by Wall St. Rank held Mereo BioPharma as of Q1 2021.

Based on RBC Europe's 13F filing for Q1 2021, filed 9 Nov 2023.